image

IRC™ TECHNOLOGY

Our proprietary immune profiling technology provides unparalleled insight.

More +

image

R&D Platform

A novel approach anchored in a deep understanding of patient anti-tumor immune responses

More +

Therapeutic Portfolio

Atreca is applying its Immune Repertoire Capture™ technology to generate and develop a novel class of cancer immunotherapies including therapeutics that optimize anti-tumor immune responses in synergy with checkpoint inhibitors and immune activators.

Atreca_Pipeline Graphics_FINAL_2

 

 

Atreca is continuing to build a product portfolio designed to meet evolving patient needs in cancer treatment.  Based upon the ability to identify the antibodies and targets that drive a productive anti-tumor immune response, the Company’s discovery platform enables multiple classes of agents, as noted below.

 

Atreca_therapeutics_2_update

 

In addition, as a result of our research and development collaborations with a variety of partners, we have several advancing programs in non-oncology areas.

image

IRC™ TECHNOLOGY

Our proprietary immune profiling technology provides unparalleled insight.

More +

image

R&D Platform

A novel approach anchored in a deep understanding of patient anti-tumor immune responses

More +